Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, with reference to research by Christine Camacho and Luke Munford at the University of Manchester showing that deaths from drugs, alcohol and suicide are higher in northern and coastal local authorities, what steps they are taking to address that regional inequality.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Levelling Up the United Kingdom white paper sets out the Government’s ambition to improve living standards and wellbeing across the UK, invest in communities, and improve public services. It sets mutually reinforcing levelling up missions to focus Government action, including a health mission to narrow the gap in healthy life expectancy by 2030, and increase healthy life expectancy by five years by 2035.
The Government has published a 10-year drug strategy and is investing an extra £532 million between 2022/23 to 2024/25 to improve drug and alcohol treatment and recovery services. This funding is being used by local authorities to create places for an additional 54,500 people in drug and alcohol treatment services and bolster the workforce, seeking to prevent nearly 1,000 deaths. This funding is being targeted to areas of highest need first.
The Department is increasingly focusing on supporting local areas, including better meeting the needs of vulnerable groups. Current work includes: providing targeted support to local areas; enhancing data tools to better inform local needs assessments; supporting workforce development; implementation of the commissioning quality standard; and sharing good practice. Implementation support will adapt over the course of the 10-year strategy in response to need, to ensure we reach the drug strategy goals.
We also published our new Suicide Prevention Strategy for England in September 2023, setting out the actions we will take to save lives and reduce suicides within the next few years, and have set out our intention in the strategy to write guidance for local areas to support them in aligning their own strategies with the national strategy. We have also established a £10 million Suicide Prevention Grant Fund to run from 2023 to March 2025, and on 4 March 2024 we announced the 79 organisations across the country that have been allocated funding. We have also launched a new nationwide, near real-time suspected suicide surveillance system, that will improve the early detection of, and timely action to, address changes in suicide rates or trends.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, with reference to research by Christine Camacho and Luke Munford at the University of Manchester, what steps they are taking to reduce regional inequalities in what those researchers refer to as "Deaths of Despair".
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Levelling Up the United Kingdom white paper sets out the Government’s ambition to improve living standards and wellbeing across the UK, invest in communities, and improve public services. It sets mutually reinforcing levelling up missions to focus Government action, including a health mission to narrow the gap in healthy life expectancy by 2030, and increase healthy life expectancy by five years by 2035.
The Government has published a 10-year drug strategy and is investing an extra £532 million between 2022/23 to 2024/25 to improve drug and alcohol treatment and recovery services. This funding is being used by local authorities to create places for an additional 54,500 people in drug and alcohol treatment services and bolster the workforce, seeking to prevent nearly 1,000 deaths. This funding is being targeted to areas of highest need first.
The Department is increasingly focusing on supporting local areas, including better meeting the needs of vulnerable groups. Current work includes: providing targeted support to local areas; enhancing data tools to better inform local needs assessments; supporting workforce development; implementation of the commissioning quality standard; and sharing good practice. Implementation support will adapt over the course of the 10-year strategy in response to need, to ensure we reach the drug strategy goals.
We also published our new Suicide Prevention Strategy for England in September 2023, setting out the actions we will take to save lives and reduce suicides within the next few years, and have set out our intention in the strategy to write guidance for local areas to support them in aligning their own strategies with the national strategy. We have also established a £10 million Suicide Prevention Grant Fund to run from 2023 to March 2025, and on 4 March 2024 we announced the 79 organisations across the country that have been allocated funding. We have also launched a new nationwide, near real-time suspected suicide surveillance system, that will improve the early detection of, and timely action to, address changes in suicide rates or trends.
Asked by: Lord Swire (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what progress they have made on integrating social care and the NHS.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Health and Care Act 2022 established integrated care systems, reforming how health and adult social care work together by putting partnership at the heart of planning. The Government has published guidance for integrated care partnerships (ICPs), on the statutory requirement for each ICP to publish an Integrated Care Strategy to address the health, social care, and public health needs of their system. All ICPs have now published their integrated care strategies.
The integration of health and social care is often best achieved through collaboration across smaller geographies within integrated care systems called places. Since the Health and Care Act 2022, we have seen good progress in the development of place-based arrangements to integrate health and social care. In October 2023, we published our Shared Outcomes Toolkit designed to help place-based partnerships develop shared outcomes as a powerful means of promoting integrated working and joined up care. We also issued a call for evidence as part of our review of Section 75 of the NHS Act 2006, which permits local authorities and National Health Service bodies to pool budgets, enabling joint commissioning and the commissioning of integrated services. The findings of this review will be shared in due course.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has made a recent assessment of the potential merits of creating a national naloxone programme.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Naloxone is highly effective in reducing opioid overdose-related deaths, and the Government is working to widen access to, and increase the uptake of, this life saving drug. A prescription only medicine that is available across the United Kingdom, naloxone can be prescribed by a doctor or non-medical prescriber or provided, under a Patient Group Direction. It can also be supplied without prescription by drug services, which include specialist National Health Service and voluntary sector treatment services, as well as community pharmacies providing other substance misuse services across the UK.
Naloxone has been available for anyone to use in an emergency since 2005. There is good awareness of it, supported by earlier guidance by the Department and its agencies in 2015, 2018, 2019, and 2023. Drug treatment services and their suppliers also provide independent awareness-raising materials, targeting people who use opioids.
The Government launched a UK-wide public consultation to seek views on our proposal to amend the Human Medicines Regulations 2012 so that more professionals, services, and family members can give out take-home naloxone supplies. The consultation closed on 6 March 2024, and the responses are currently being analysed. The Government will publish its official response shortly.
The Government is working to increase naloxone carriage, and has provided additional investment in drug treatment services to support this work. In England, local authorities and their partners have been increasing naloxone supply in recent years. There are now three naloxone products available, and supply has been meeting demand. To enable the Government to respond to any future change in demand for naloxone, the Department is working with the Home Office to model scenarios where demand for naloxone may increase, and has conducted a commercial engagement exercise to better understand the naloxone market, and the market’s capacity to respond to changes in demand.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what her planned timetable is for publishing a response to her Department's consultation on Expanding access to naloxone.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Naloxone is highly effective in reducing opioid overdose-related deaths, and the Government is working to widen access to, and increase the uptake of, this life saving drug. A prescription only medicine that is available across the United Kingdom, naloxone can be prescribed by a doctor or non-medical prescriber or provided, under a Patient Group Direction. It can also be supplied without prescription by drug services, which include specialist National Health Service and voluntary sector treatment services, as well as community pharmacies providing other substance misuse services across the UK.
Naloxone has been available for anyone to use in an emergency since 2005. There is good awareness of it, supported by earlier guidance by the Department and its agencies in 2015, 2018, 2019, and 2023. Drug treatment services and their suppliers also provide independent awareness-raising materials, targeting people who use opioids.
The Government launched a UK-wide public consultation to seek views on our proposal to amend the Human Medicines Regulations 2012 so that more professionals, services, and family members can give out take-home naloxone supplies. The consultation closed on 6 March 2024, and the responses are currently being analysed. The Government will publish its official response shortly.
The Government is working to increase naloxone carriage, and has provided additional investment in drug treatment services to support this work. In England, local authorities and their partners have been increasing naloxone supply in recent years. There are now three naloxone products available, and supply has been meeting demand. To enable the Government to respond to any future change in demand for naloxone, the Department is working with the Home Office to model scenarios where demand for naloxone may increase, and has conducted a commercial engagement exercise to better understand the naloxone market, and the market’s capacity to respond to changes in demand.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment she has made of the availability of naloxone across England.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Naloxone is highly effective in reducing opioid overdose-related deaths, and the Government is working to widen access to, and increase the uptake of, this life saving drug. A prescription only medicine that is available across the United Kingdom, naloxone can be prescribed by a doctor or non-medical prescriber or provided, under a Patient Group Direction. It can also be supplied without prescription by drug services, which include specialist National Health Service and voluntary sector treatment services, as well as community pharmacies providing other substance misuse services across the UK.
Naloxone has been available for anyone to use in an emergency since 2005. There is good awareness of it, supported by earlier guidance by the Department and its agencies in 2015, 2018, 2019, and 2023. Drug treatment services and their suppliers also provide independent awareness-raising materials, targeting people who use opioids.
The Government launched a UK-wide public consultation to seek views on our proposal to amend the Human Medicines Regulations 2012 so that more professionals, services, and family members can give out take-home naloxone supplies. The consultation closed on 6 March 2024, and the responses are currently being analysed. The Government will publish its official response shortly.
The Government is working to increase naloxone carriage, and has provided additional investment in drug treatment services to support this work. In England, local authorities and their partners have been increasing naloxone supply in recent years. There are now three naloxone products available, and supply has been meeting demand. To enable the Government to respond to any future change in demand for naloxone, the Department is working with the Home Office to model scenarios where demand for naloxone may increase, and has conducted a commercial engagement exercise to better understand the naloxone market, and the market’s capacity to respond to changes in demand.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she is taking steps to increase awareness of naloxone.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Naloxone is highly effective in reducing opioid overdose-related deaths, and the Government is working to widen access to, and increase the uptake of, this life saving drug. A prescription only medicine that is available across the United Kingdom, naloxone can be prescribed by a doctor or non-medical prescriber or provided, under a Patient Group Direction. It can also be supplied without prescription by drug services, which include specialist National Health Service and voluntary sector treatment services, as well as community pharmacies providing other substance misuse services across the UK.
Naloxone has been available for anyone to use in an emergency since 2005. There is good awareness of it, supported by earlier guidance by the Department and its agencies in 2015, 2018, 2019, and 2023. Drug treatment services and their suppliers also provide independent awareness-raising materials, targeting people who use opioids.
The Government launched a UK-wide public consultation to seek views on our proposal to amend the Human Medicines Regulations 2012 so that more professionals, services, and family members can give out take-home naloxone supplies. The consultation closed on 6 March 2024, and the responses are currently being analysed. The Government will publish its official response shortly.
The Government is working to increase naloxone carriage, and has provided additional investment in drug treatment services to support this work. In England, local authorities and their partners have been increasing naloxone supply in recent years. There are now three naloxone products available, and supply has been meeting demand. To enable the Government to respond to any future change in demand for naloxone, the Department is working with the Home Office to model scenarios where demand for naloxone may increase, and has conducted a commercial engagement exercise to better understand the naloxone market, and the market’s capacity to respond to changes in demand.
Asked by: Anthony Mangnall (Conservative - Totnes)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, what estimate she has made of the average cost per household of replacing a telecare system to accommodate the BT Digital Voice migration in (a) a private residence, (b) a retirement housing community and (c) a care home; and whether these costs include the provision of (i) battery backup systems and (ii) replacement of associated systems such as (A) lift alarms, (B) fire safety alarms and (C) intercom equipment.
Answered by Julia Lopez - Minister of State (Department for Science, Innovation and Technology)
Given the range of telecare systems, lifeline alarm systems or remote ringers available on the market, we cannot definitively provide cost estimates for replacing a device. Telecare devices can come with a range of potential add-ons that may increase costs, including but not limited to additional power resilience (such as multi-SIM connectivity solutions); personalised support (such as a dedicated helpline); and/or additional monitoring (such as tracking health data like heart rate or blood pressure).
It should be noted that the migration from analogue to digital landlines (also known as the Public Switched Telephone Network (PSTN) migration) is not specific to BT; other telecoms providers are also upgrading their analogue lines. Furthermore, the telecoms industry is not responsible for the provision or maintenance of telecare devices.
The government is working closely with telecoms companies, Local Authorities and telecare services providers to understand how the migration may impact telecare users and what more can be done to mitigate risks associated with the migration. For example, all major communications providers (including BT and Virgin Media O2) have signed up to a PSTN Charter where they commit not to migrate telecare users without a full confirmation that they have a compatible and functioning telecare solution in place.
Asked by: Peter Dowd (Labour - Bootle)
Question to the HM Treasury:
To ask the Chancellor of the Exchequer, with reference to the Spring Budget 2024, whether he has made an estimate of the potential return on investment of (a) violence reduction units, (b) hot spot policing, (c) increasing the capacity of children's homes and (d) the building of 15 new special free schools.
Answered by Laura Trott - Chief Secretary to the Treasury
These measures are part of the Public Sector Productivity Review, which will deliver up to £1.8 billion worth of benefits by 2029.
We have committed £75 million to expand the Violence Reduction Unit model across England and Wales, supporting a prevention-first approach to serious violence. Violence Reduction Units enable local public services such as health boards, schools and police leaders to coordinate their joint strategy to tackle serious violence among young people, preventing violent crime and reducing burdens on healthcare, schools and criminal justice.
As part of the Anti-Social Behaviour Action Plan, we committed £66.3 million to scale up hotspot enforcement. From April 2024, hotspot response will be rolled out across every police force area in England and Wales, which will see thousands of additional high visibility patrols in the places most affected by Serious Violence and Anti-Social Behaviour.
An independent evaluation found that in 2022/23, VRUs and hotspot policing prevented 3,220 hospital admissions from violent injury – a statistically significant drop. Please find a link to the evaluation here: https://www.gov.uk/government/publications/violence-reduction-units-year-ending-march-2023-evaluation-report/violence-reduction-units-2022-to-2023#:~:text=In%202022%2C%20a%20further%202,data%20sharing%20and%20analysis.
On increasing the capacity of children’s homes, the Government announced £165 million of funding over the next 4 years to reduce the reliance of local authorities on costly emergency provision.
Finally, the building of 15 new special free schools through £105 million of investment over the next 4 years will deliver over 2,000 additional special places for children with special education needs and disabilities.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the extent to which the 2021 NICE guidance for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) has been implemented (1) in general, and (2) in relation to the training health and social care professionals on how to employ the new recommendations, (a) establishing a UK-wide network of hospital-based ME/CFS specialist services, (b) making all NHS services accessible and capable of providing personalised ongoing care and support to those with ME/CFS, and (c) ensuring social care provision for ME/CFS is monitored and regularly reviewed.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
No formal assessment has been made of the extent to which the 2021 National Institute for Health and Care Excellence (NICE) guidance for myalgic encephalomyelitis (ME), also known as chronic fatigue syndrome (CFS), has been implemented.
NHS England does not centrally commission services for ME. Services to support people living with ME are commissioned by integrated care boards (ICBs) to meet the needs of their local population, and are not reviewed or assessed by NHS England centrally. In October 2023, the British Association of Clinicians in ME published their ME/CFS National Services Survey 2023. This survey provides insight on the services being delivered for adults, and children and young people, living with ME. A copy of the survey is attached.
In relation to the training of health and social care professionals, it is the duty of clinicians to keep themselves appraised of best practice, in particular guidance issued by the NICE. The Department is working with NHS England to develop an e-learning course on ME for healthcare professionals, with the aim of supporting staff to be able to provide better care and improve patient outcomes. This has involved feedback and input from the ME Research Collaborative (MERC) Patient Advisory Group. The Medical Schools Council will promote the NHS England e-learning package on ME to all United Kingdom medical schools, and encourage medical schools to provide undergraduates with direct patient experience of ME.
The Department published My full reality: an interim delivery plan for ME/CFS in August 2023, which sets out a number of actions to improve the experiences and outcomes for people living with the condition, including better education of professionals and improvements to service provision. More information about the interim plan is available on the GOV.UK website, in an online only format.
Alongside the publication of the interim delivery plan, we ran a public consultation to build a picture of how well the plan meets the needs of the ME community, and to understand if there are any gaps where further action may be necessary. The Department is currently analysing over 3,000 responses to the consultation on the interim delivery plan on ME, and will publish a final delivery plan later this year.
In relation to the monitoring of social care provision for individuals with ME, the Department has made a landmark shift in how we hold local authorities to account for their adult social care duties, through a new Care Quality Commission (CQC) assessment. The CQC will examine how well local authorities deliver their Care Act duties, increasing transparency and accountability and, most importantly, driving improved outcomes for people, including those with ME, who draw on care and support. The CQC completed five pilot assessments and is now rolling out assessment to all local authorities.